Icon

REMODULIN (nda021272)- (0.1MG/ML,0.2MG/ML,0.4MG/ML,1MG/ML,2.5MG/ML,5MG/ML,10MG/ML,20MG/ML)

TREPROSTINIL UNITED THERAP
0.1MG/ML,0.2MG/ML,0.4MG/ML,1MG/ML,2.5MG/ML,5MG/ML,10MG/ML,20MG/ML
Yes No
2029-Mar-29 Expired
None None
None No
Remodulin is a prostacyclin vasodilator indicated for: • Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). • Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.
5 0 4
Total Other Developers None
Drugs with Suitability No
0.1MG/ML ** ** - - -
0.2MG/ML ** ** - - -
0.4MG/ML ** ** - - -
1MG/ML ** ** - - -
2.5MG/ML ** ** - - -
5MG/ML ** ** - - -
10MG/ML ** ** - - -
20MG/ML ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 3
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** *** ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** ******* ****** ****** ****** *** *********** ***** ****'********* *, ********, *****, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.